Table 3.
JAK2V617F allele burden (ITT population).
| Timepoint | Absolute JAK2V617F allele burden, % |
|---|---|
| Real baseline (N = 50) | 60.1 ± 18.94 |
| Year 1 (N = 42) | 48.5 ± 20.01 |
| Year 2 (N = 19) | 50.6 ± 21.49 |
| Year 3 (N = 11) | 58.9 ± 26.86 |
| Year 4 (N = 10) | 47.2 ± 24.71 |
| Year 5 (N = 9) | 42.1 ± 14.05 |
Note that as this is an ongoing study, patients currently in the study have received varying durations of therapy. At the time of these analyses, 31 patients were still in the study. Data are mean ± standard deviation.
JAK Janus kinase.